OS Therapies Inc — Form 8-K/A
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
OS Therapies and Leonite Fund I, LP executed a side letter (June 30, 2026) modifying terms of a $10M senior secured convertible note and 1.75M share warrant. The letter delays anti-dilution adjustment effectiveness to September 30, 2026 for any dilutive issuances occurring on or before September 29, 2026, and redefines the $5M carve-out threshold to require gross proceeds in a single closing rather than aggregating multiple tranches. No dollar amounts, share counts, or other substantive terms changed; only timing and aggregation mechanics were modified.
Why this rating
Administrative amendment to existing $10M financing (20% of market cap). Delays anti-dilution mechanics 3 months; no new capital infusion, no immediate dilution, no strategic shift.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.